Antiproliferative Activity of microRNA-125a and its Molecular Targets

Author(s): Aniello Russo*, Nicoletta Potenza.

Journal Name: MicroRNA

Volume 8 , Issue 3 , 2019

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Background: MicroRNA-125a is present in all animals with bilateral symmetry and displays a conserved nucleotide sequence with a section of 11 bases including the seed region that is identical in all considered species. It primarily downregulates the expression of LIN28, thereby promoting cell differentiation and larval phase transitions in nematodes, mammals and insects.

Objective: In this review, we focus on the cellular control of miR-125a expression and its antiproliferative activity.

Results: In mammalians, microRNA-125a is present in most adult organs and tissues in which it targets proteins involved in the mitogenic response, such as membrane receptors, intracellular signal transducers, or transcription factors, with the overall effect of inhibiting cell proliferation. Tissue levels of miR-125a generally raise during differentiation but it is often downregulated in cancers, e.g. colon, cervical, gastric, ovarian, lung, and breast cancers, osteosarcoma, neuroblastoma, glioblastoma, medulloblastoma, retinoblastoma and hepatocellular carcinoma.

Conclusion: The antiproliferative activity of miR-125a, demonstrated in many cell types, together with the notion that this miRNA is downregulated in several kinds of cancers, give a substantial support to the concept that miR-125a plays an oncosuppressive role.

Keywords: Cancer, cell cultures, hepatocellular carcinoma, microRNA, oncosuppressor, RNA interference.

[1]
Potenza N, Russo A. Biogenesis, evolution and functional targets of microRNA-125a. Mol Genet Genomics 2013; 288: 381-9.
[2]
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-54.
[3]
Moss EG, Lee RC, Ambros V. The cold shock domain protein LIN-28 controls developmental timing in C. elegans and is regulated by the lin-4 RNA. Cell 1997; 88: 637-46.
[4]
Caygill EE, Johnston LA. Temporal regulation of metamorphic processes in Drosophila by the let-7 and miR-125 heterochronic microRNAs. Curr Biol 2008; 18: 943-50.
[5]
Wu L, Belasco JG. Micro-RNA regulation of the mammalian lin-28 gene during neuronal differentiation of embryonal carcinoma cells. Mol Cell Biol 2005; 25: 9198-208.
[6]
Takashima Y, Terada M, Udono M, Miura S, Yamamoto J, Suzuki A. Suppression of lethal-7b and miR-125a/b maturation by Lin28b enables maintenance of stem cell properties in hepatoblasts. Hepatology 2016; 64: 245-60.
[7]
Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-20.
[8]
Aloia L, Parisi S, Fusco L, Pastore L, Russo T. Differentiation of embryonic stem cells 1 (Dies1) is a component of bone morphogenetic protein 4 (BMP4) signaling pathway required for proper differentiation of mouse embryonic stem cells. J Biol Chem 2010; 285: 7776-83.
[9]
Parisi S, Battista M, Musto A, Navarra A, Tarantino C. Russo TA regulatory loop involving Dies1 and miR-125a controls BMP4 signaling in mouse embryonic stem cells. FASEB J 2012; 26: 3957-68.
[10]
Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
[11]
Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 2006; 103: 7024-9.
[12]
Negrini M, Ferracin M, Sabbioni S, Croce CM. MicroRNAs in human cancer: from research to therapy. J Cell Sci 2007; 120: 1833-40.
[13]
Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol 2014; 9: 287-314.
[14]
Liu YP, Berkhout B. Design of lentivirally expressed siRNAs. Methods Mol Biol 2013; 942: 233-57.
[15]
Wagner E. Polymers for nucleic acid transfer-an overview. Adv Genet 2014; 88: 231-61.
[16]
Tominaga N, Yoshioka Y, Ochiya T. A novel platform for cancer therapy using extracellular vesicles. Adv Drug Deliv Rev 2015; 95: 50-5.
[17]
Barata P, Sood AK, Hong DS. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treat Rev 2016; 50: 35-47.
[18]
Lorenzetti D, Poirier C, Zhao M, Overbeek PA, Harrison W, Bishop CE. A transgenic insertion on mouse chromosome 17 inactivates a novel immunoglobulin superfamily gene potentially involved in sperm-egg fusion. Mamm Genome 2014; 25: 141-8.
[19]
Potenza N, Panella M, Castiello F, Mosca N, Amendola E, Russo A. Molecular mechanisms governing microRNA-125a expression in human hepatocellular carcinoma cells. Sci Rep 2017; 7: 10712.
[20]
De la Rica L, García-Gómez A, Comet NR, et al. NF-κB-direct activation of microRNAs with repressive effects on monocyte-specific genes is critical for osteoclast differentiation. Genome Biol 2015; 16: 2.
[21]
Coppola N, Potenza N, Pisaturo M, et al. Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS One 2013; 8: e65336.
[22]
Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC. MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA 2012; 109: 7865-70.
[23]
Mosca N, Castiello F, Coppola N, et al. Functional interplay between hepatitis B virus X protein and human miR-125a in HBV infection. Biochem Biophys Res Commun 2014; 449: 141-5.
[24]
Potenza N, Papa U, Mosca N, Zerbini F, Nobile V, Russo A. Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucleic Acids Res 2011; 39: 5157-63.
[25]
Park SO, Kumar M, Gupta S. TGF-β and iron differently alter HBV replication in human hepatocytes through TGF-β/BMP signaling and cellular microRNA expression. PLoS One 2012; 7: e39276.
[26]
Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell 2013; 152: 1298-307.
[27]
Autuoro JM, Pirnie SP, Carmichael GG. Long noncoding RNAs in imprinting and X chromosome inactivation. Biomolecules 2014; 4: 76-100.
[28]
Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014; 505: 344-52.
[29]
Chai L, Yuan Y, Chen C, Zhou J, Wu Y. The role of long non-coding RNA ANRIL in the carcinogenesis of oral cancer by targeting miR-125a. Biomed Pharmacother 2018; 103: 38-45.
[30]
Li R, Yin F, Guo YY, Zhao KC, Ruan Q, Qi YM. Knockdown of ANRIL aggravates H2O2-induced injury in PC-12 cells by targeting microRNA-125a. Biomed Pharmacother 2017; 92: 952-61.
[31]
Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science 2008; 320: 97-100.
[32]
Van Wynsberghe PM, Kai ZS, Massirer KB, et al. LIN-28 co-transcriptionally binds primary let-7 to regulate miRNA maturation in Caenorhabditis elegans. Nat Struct Mol Biol 2011; 18: 302-8.
[33]
Panella M, Mosca N, Di Palo A, Potenza N, Russo A. Mutual suppression of miR-125a and Lin28b in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2018; 500: 824-7.
[34]
Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479-86.
[35]
Wang S, Huang J, Lyu H, et al. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis 2013; 4: e556.
[36]
Ufkin ML, Peterson S, Yang X, Driscoll H, Duarte C, Sathyanarayana P. miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk Res 2014; 38: 402-10.
[37]
Bi Q, Tang S, Xia L, et al. Ectopic expression of miR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One 2012; 7: e40169.
[38]
Potenza N, Mosca N, Zappavigna S, et al. MicroRNA-125a-5p is a downstream effector of sorafenib in its antiproliferative activity toward human hepatocellular carcinoma cells. J Cell Physiol 2017; 232: 1907-13.
[39]
Laneve P, Di Marcotullio L, Gioia U, et al. The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci USA 2007; 104: 7957-62.
[40]
Kim JK, Noh JH, Jung KH, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors miR-125a-5p and miR-125b. Hepatology 2013; 57: 1055-67.
[41]
Kong J, Liu X, Li X, et al. miR-125/Pokemon auto-circuit contributes to the progression of hepatocellular carcinoma. Tumour Biol 2016; 37: 511-9.
[42]
Coppola N, de Stefano G, Panella M, et al. Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf. Oncotarget 2017; 8: 25289-99.
[43]
Fan Z, Cui H, Xu X, et al. MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3. Oncotarget 2015; 6: 25266-80.
[44]
Fan Z, Cui H, Yu H, et al. MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression. Oncogenesis 2016; 5: e197.
[45]
Zhong L, Sun S, Shi J, Cao F, Han X, Chen Z. MicroRNA-125a-5p plays a role as a tumor suppressor in lung carcinoma cells by directly targeting STAT3. Tumour Biol 2017; 39: 1010428317697579.
[46]
Zhao Y, Ma K, Yang S, et al. MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. Int J Oncol 2018; 53: 644-58.
[47]
Tao T, Shen Q, Luo J, Xu Y, Liang W. MicroRNA-125a regulates cell proliferation via directly targeting E2F2 in osteosarcoma. Cell Physiol Biochem 2017; 43: 768-74.
[48]
Xu Y, Huang Z, Liu Y. Reduced miR-125a-5p expression is associated with gastric carcinogenesis through the targeting of E2F3. Mol Med Rep 2014; 10: 2601-8.
[49]
Yuan J, Xiao G, Peng G, et al. MiRNA-125a-5p inhibits glioblastoma cell proliferation and promotes cell differentiation by targeting TAZ. Biochem Biophys Res Commun 2015; 457: 171-6.
[50]
Tatsumi N, Hojo N, Yamada O, et al. Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities. Oncogene 2016; 35: 1003-14.
[51]
Makwana K, Patel SA, Velingkaar N, Ebron JS, Shukla GC, Kondratov RVKV. Aging and calorie restriction regulate the expression of miR-125a-5p and its target genes Stat3, Casp2 and Stard13. Aging 2017; 9: 1825-43.
[52]
Umbach JL, Cullen BR. The role of RNAi and microRNAs in animal virus replication and antiviral immunity. Genes Dev 2009; 23: 1151-64.
[53]
Russo A, Potenza N. Antiviral effects of human microRNAs and conservation of their target sites. FEBS Lett 2011; 585: 2551-5.
[54]
Hu W, Wang X, Ding X, et al. MicroRNA-141 represses HBV replication by targeting PPARA. PLoS One 2012; 7: e34165.
[55]
Coppola N, Onorato L, Panella M, et al. Correlation between the hepatic expression of human microRNA hsa-miR-125a-5p and the progression of fibrosis in patients with overt and occult HBV infection. Front Immunol 2018; 9: 1334.
[56]
Momeni M, Hassanshahi G, Arababadi MK, Kennedy D. Ectopic expression of micro-RNA-1, 21 and 125a in peripheral blood immune cells is associated with chronic HBV infection. Mol Biol Rep 2014; 41: 4833-7.
[57]
Zhou J, Ng SB, Chng WJ. LIN28/LIN28B: an emerging oncogenic driver in cancer stem cells. Int J Biochem Cell Biol 2013; 45: 973-8.
[58]
Wang H, Zhao Q, Deng K, et al. Lin28: an emerging important oncogene connecting several aspects of cancer. Tumour Biol 2016; 37: 2841-8.
[59]
Nguyen LH, Robinton DA, Seligson MT, et al. Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. Cancer Cell 2014; 26: 248-61.
[60]
Molenaar JJ, Domingo-Fernández R, Ebus ME, et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 2012; 44: 1199-206.
[61]
Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J 2012; 18: 215-22.
[62]
Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-9.
[63]
Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
[64]
Weber B, Stresemann C, Brueckner B, Lyko F. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 2007; 6: 1001-5.
[65]
Li W, Duan R, Kooy F, Sherman SL, Zhou W, Jin P. Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet 2009; 46: 358-60.
[66]
Cai M, Chen Q, Shen J, Lv C, Cai L. Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer. J Cell Mol Med 2018; 22(10): 4721-31.
[67]
Qin X, Wan Y, Wang S, Xue M. MicroRNA-125a-5p modulates human cervical carcinoma proliferation and migration by targeting ABL2. Drug Des Devel Ther 2015; 10: 71-9.
[68]
Song C, Wu G, Xiang A, et al. Over-expression of miR-125a-5p inhibits proliferation in C2C12 myoblasts by targeting E2F3. Acta Biochim Biophys Sin 2015; 47: 244-9.
[69]
Chen P, Wang H, Yang F, Chen H, He W, Wang J. Curcumin promotes osteosarcoma cell death by activating mir-125a/errα signal pathway. J Cell Biochem 2017; 118: 74-81.
[70]
Tiwari A, Shivananda S, Gopinath KS, Kumar A. MicroRNA-125a reduces proliferation and invasion of oral squamous cell carcinoma cells by targeting estrogen-related receptor α: implications for cancer therapeutics. J Biol Chem 2014; 289: 32276-90.
[71]
Guo X, Wu Y, Hartley RS. MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol 2009; 6: 575-83.
[72]
Zhang Y, Xue C, Zhu X, Zhu X, Xian H, Huang Z. Suppression of microRNA-125a-5p upregulates the TAZ-EGFR signaling pathway and promotes retinoblastoma proliferation. Cell Signal 2016; 28: 850-60.
[73]
Hojo N, Tatsumi N, Moriguchi N, et al. A Zbtb7a proto-oncogene as a novel target for miR-125a. Mol Carcinog 2016; 55: 2001-9.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 8
ISSUE: 3
Year: 2019
Page: [173 - 179]
Pages: 7
DOI: 10.2174/2211536608666181105114739

Article Metrics

PDF: 39
HTML: 8